Microdissecting the Hypoxia Landscape in Colon Cancer Reveals Three Distinct Subtypes and Their Potential Mechanism to Facilitate the Development of Cancer.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
09
2022
revised:
09
10
2022
accepted:
25
11
2022
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Hypoxia contributes to tumor progression and confers drug resistance. We attempted to microdissect the hypoxia landscape in colon cancer (CC) and explore its correlation with immunotherapy response. The hypoxia landscape in CC patients was microdissected through unsupervised clustering. The "xCell" algorithms were applied to decipher the tumor immune infiltration characteristics. A hypoxia-related index signature was developed via the LASSO (least absolute shrinkage and selection operator) Cox regression in The Cancer Genome Atlas (TCGA)-colon adenocarcinoma (COAD) cohort and validated in an independent dataset from the Gene Expression Omnibus (GEO) database. The tumor immune dysfunction and exclusion (TIDE) algorithm was utilized to evaluate the correlation between the hypoxia-related index (HRI) signature and immunotherapy response. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blotting were performed to verify the mRNA expression levels of five key genes. The Cell Counting Kit-8 (CCK-8) assay and flow cytometry were performed to examine the cell viability and cell apoptosis. Patients were classified into hypoxia-high, hypoxia-median, and hypoxia-low clusters in TCGA-COAD and verified in the GSE 17538 dataset. Compared with the hypoxia-low cluster, the hypoxia-high cluster consistently presented an unfavorable prognosis, higher immune scores, and stromal scores and elevated infiltration levels of several critical immune and stromal cells. Otherwise, we also found 600 hypoxia-related differentially expressed genes (HRDEGs) between the hypoxia-high cluster and the hypoxia-low cluster. Based on the 600 HRDEGs, we constructed the HRI signature which consists of 11 genes and shows a good prognostic value in both TCGA-COAD and GSE 17538 (AUC of 6-year survival prediction >0.75). Patients with low HRI scores were consistently predicted to be more responsive to immunotherapy. Of the 11 HRI signature genes, RGS16, SNAI1, CDR2L, FRMD5, and FSTL3 were differently expressed between tumors and adjacent tissues. Low expression of SNAI1, CDR2L, FRMD5, and FSTL3 could induce cell viability and promote tumor cell apoptosis. In our study, we discovered three hypoxia clusters which correlate with the clinical outcome and the tumor immune microenvironment in CC. Based on the hypoxia cluster and HRDEGs, we constructed a reliable HRI signature that could accurately predict the prognosis and immunotherapeutic responsiveness in CC patients and discovered four key genes that could affect tumor cell viability and apoptosis.
Sections du résumé
Background
UNASSIGNED
Hypoxia contributes to tumor progression and confers drug resistance. We attempted to microdissect the hypoxia landscape in colon cancer (CC) and explore its correlation with immunotherapy response.
Materials and Methods
UNASSIGNED
The hypoxia landscape in CC patients was microdissected through unsupervised clustering. The "xCell" algorithms were applied to decipher the tumor immune infiltration characteristics. A hypoxia-related index signature was developed via the LASSO (least absolute shrinkage and selection operator) Cox regression in The Cancer Genome Atlas (TCGA)-colon adenocarcinoma (COAD) cohort and validated in an independent dataset from the Gene Expression Omnibus (GEO) database. The tumor immune dysfunction and exclusion (TIDE) algorithm was utilized to evaluate the correlation between the hypoxia-related index (HRI) signature and immunotherapy response. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blotting were performed to verify the mRNA expression levels of five key genes. The Cell Counting Kit-8 (CCK-8) assay and flow cytometry were performed to examine the cell viability and cell apoptosis.
Results
UNASSIGNED
Patients were classified into hypoxia-high, hypoxia-median, and hypoxia-low clusters in TCGA-COAD and verified in the GSE 17538 dataset. Compared with the hypoxia-low cluster, the hypoxia-high cluster consistently presented an unfavorable prognosis, higher immune scores, and stromal scores and elevated infiltration levels of several critical immune and stromal cells. Otherwise, we also found 600 hypoxia-related differentially expressed genes (HRDEGs) between the hypoxia-high cluster and the hypoxia-low cluster. Based on the 600 HRDEGs, we constructed the HRI signature which consists of 11 genes and shows a good prognostic value in both TCGA-COAD and GSE 17538 (AUC of 6-year survival prediction >0.75). Patients with low HRI scores were consistently predicted to be more responsive to immunotherapy. Of the 11 HRI signature genes, RGS16, SNAI1, CDR2L, FRMD5, and FSTL3 were differently expressed between tumors and adjacent tissues. Low expression of SNAI1, CDR2L, FRMD5, and FSTL3 could induce cell viability and promote tumor cell apoptosis.
Conclusion
UNASSIGNED
In our study, we discovered three hypoxia clusters which correlate with the clinical outcome and the tumor immune microenvironment in CC. Based on the hypoxia cluster and HRDEGs, we constructed a reliable HRI signature that could accurately predict the prognosis and immunotherapeutic responsiveness in CC patients and discovered four key genes that could affect tumor cell viability and apoptosis.
Identifiants
pubmed: 36925652
doi: 10.1155/2023/9346621
pmc: PMC10014161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9346621Informations de copyright
Copyright © 2023 Pingfei Tang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Aging (Albany NY). 2021 Aug 23;13(16):20302-20318
pubmed: 34425560
Cancer Lett. 2019 Aug 28;458:13-20
pubmed: 31136782
J Exp Clin Cancer Res. 2018 Dec 29;37(1):327
pubmed: 30594216
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E5990-E5999
pubmed: 29891662
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cancer Lett. 2019 Mar 1;444:60-69
pubmed: 30583072
Ann Surg Oncol. 2009 Dec;16(12):3507-14
pubmed: 19760045
Onco Targets Ther. 2020 Apr 01;13:2725-2738
pubmed: 32280246
Mol Biol Rep. 2022 Sep;49(9):8761-8775
pubmed: 35771357
Semin Cancer Biol. 2020 Oct;65:140-154
pubmed: 31927131
Sci Rep. 2020 Jun 24;10(1):10258
pubmed: 32581224
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Nat Rev Cancer. 2014 Jun;14(6):430-9
pubmed: 24827502
Int J Mol Sci. 2021 Jun 23;22(13):
pubmed: 34201607
Science. 2016 Apr 8;352(6282):175-80
pubmed: 27124451
Cancer Res. 2017 Aug 15;77(16):4305-4316
pubmed: 28652251
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Front Genet. 2021 Nov 30;12:785185
pubmed: 34917132
Mol Ther. 2018 Mar 7;26(3):744-754
pubmed: 29475734
Aging (Albany NY). 2021 Sep 23;13(18):22528-22543
pubmed: 34555811
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Sci Rep. 2019 Feb 12;9(1):1803
pubmed: 30755640
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471
pubmed: 28710511
Mol Cancer. 2019 Nov 11;18(1):157
pubmed: 31711497
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):15-22
pubmed: 30006019
Mol Ther. 2019 Oct 2;27(10):1810-1824
pubmed: 31208913
Cancer Sci. 2017 Apr;108(4):612-619
pubmed: 28117551
Gastroenterology. 2019 Sep;157(3):823-837
pubmed: 31078621
Cell Metab. 2018 Feb 6;27(2):281-298
pubmed: 29129785
Mol Cancer. 2020 Apr 2;19(1):71
pubmed: 32241279
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Cell Death Dis. 2020 Jul 31;11(7):610
pubmed: 32737283
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Cancers (Basel). 2020 Apr 02;12(4):
pubmed: 32252351
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Gastroenterology. 2017 Aug;153(2):505-520
pubmed: 28435028
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Physiol Rev. 2020 Jan 1;100(1):1-102
pubmed: 31414610
Clin Cancer Res. 2018 Dec 15;24(24):6331-6344
pubmed: 29945992
J Stat Softw. 2011 Mar;39(5):1-13
pubmed: 27065756
Front Cell Dev Biol. 2021 Apr 20;9:665364
pubmed: 33959617
Cancer Cell Int. 2019 Sep 23;19:243
pubmed: 31572060
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
J Exp Clin Cancer Res. 2021 Jan 9;40(1):24
pubmed: 33422072